Anti-KLK7/Kallikrein 7(PRSS6) antibody

Anti-KLK7/Kallikrein 7(PRSS6) antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit polyclonal to KLK7/Kallikrein 7(PRSS6)

ELISA, IHC-P

Human Kallikrein-7 / KLK7

hK7 antibody; hSCCE antibody; Kallikrein 7 antibody; Kallikrein 7 antibody; Klk7 antibody; Prss6 antibody; PRSS6 antibody; SCCE antibody; SCCE antibody; Klk7 antibody; hK7 antibody; SCCE antibody; PRSS6 antibody; SCCE antibody; Prss6 antibody

Rabbit IgG

Produced in rabbits immunized with purified, recombinant Human KLK7 (rh KLK7; NP_005037.1; Met 1-Arg 253). KLK7 specific IgG was purified by human KLK7 affinity chromatography

Polyclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Kallikrein-7, also known as kallikrein-related peptidase 7, Stratum corneum chymotryptic enzyme, Serine protease 6, KLK7, and PRSS6, is a secreted protein which belongs to the peptidase S1 family and Kallikrein subfamily. Members of the Kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14). Kallikrein-7 / KLK7 appears to be increased in ovarian cancer and higher KLK7 expression in ovarian cancer tissue is associated with poorer prognosis of ovarian cancer patients. Kallikrein-7 / KLK7 is abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Kallikrein-7 / KLK7 is up-regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at the protein level). It was significantly associated with shorter overall survival (OS) and disease-free survival (DFS). Kallikrein-7 / KLK7 may catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. KLK7 also plays a role in the activation of precursors to inflammatory cytokines.